Drug Transporters: Their Role and Importance in the Selection and Development of New Drugs

Kusuhara, 2002, Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney, J. Control Release, 78, 43, 10.1016/S0168-3659(01)00480-1 Kim, 2000, Transporters in drug disposition, Curr. Opin. Drug Discov. Develop., 3, 94 Zhang, 1998, Role of organic cation transporters in drug absorption and elimination, Ann. Rev. Pharmacol. Toxicol., 38, 431, 10.1146/annurev.pharmtox.38.1.431 Koepsell, 1998, Organic cation transporters in intestine, kidney, liver, and brain, Ann. Rev. Physiol., 60, 243, 10.1146/annurev.physiol.60.1.243 Meijer, 1999, Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cellspecific drug delivery, Nephrol. Dial. Transplant., 14, 1, 10.1093/ndt/14.suppl_4.1b Hirohashi, 2000, ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (mrp3), J. Biol. Chem., 275, 2905, 10.1074/jbc.275.4.2905 Hirohashi, 1999, Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3), J. Biol. Chem., 274, 15181, 10.1074/jbc.274.21.15181 Gao, 2001, Organic anion transport across the chroid plexus, Microsc. Res. Tech., 52, 60, 10.1002/1097-0029(20010101)52:1<60::AID-JEMT8>3.0.CO;2-C Suzuki, 1999, Transporters for bile acids and organic anions, 387 White, 2000, High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery, Annu. Rev. Pharmacol. Toxicol., 40, 133, 10.1146/annurev.pharmtox.40.1.133 Roberts, 2001, High-throughput screening approaches for investigating drug metabolism and pharmacokinetics, Xenobiotica, 31, 557, 10.1080/00498250110060978 Kusuhara, 2001, Drug-drug interactions involving the membrane transport process, 123 Ayrton, 2001, Role of transport proteins in drug absorption, distribution and excretion, Xenobiotica, 31, 469, 10.1080/00498250110060969 Dresser, 2001, Transporters involved in the elimination of drugs in the kidney: oraganic anion transporters and organic cation transporters, J. Pharm. Sci., 90, 397, 10.1002/1520-6017(200104)90:4<397::AID-JPS1000>3.0.CO;2-D Meier, 1997, Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver, Hepatology, 26, 1667, 10.1002/hep.510260641 Hooiveld, 2001, Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport, Eur. J. Pharm. Sci., 12, 525, 10.1016/S0928-0987(01)00101-4 Lee, 2001, Pharmacogenomics of drug transporters: the next drug delivery challenge, Adv. Drug Deliv. Rev., 50, S33, 10.1016/S0169-409X(01)00186-7 Kullak-Ublick, 2001, Organic aniontransporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver, Gastroenterology, 120, 525, 10.1053/gast.2001.21176 Inui, 2000, Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2, Nephrol. Dial. Transplant., 15, 11, 10.1093/ndt/15.suppl_6.11 Konig, 2000, Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide, J. Biol. Chem., 275, 23161, 10.1074/jbc.M001448200 Tamai, 2000, Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family, Biochem. Biophys. Res. Commun., 273, 251, 10.1006/bbrc.2000.2922 Kusuhara, 1998, The role of P-glycoprotein and canalicular multispecific organic anion transporter (cMOAT) in the hepatobiliary excretion of drugs, J. Pharm. Sci., 87, 1025, 10.1021/js970100b Borst, 1999, The multidrug resistance protein family, Biochim. Biophys. Acta., 1461, 347, 10.1016/S0005-2736(99)00167-4 Greiner, 1999, The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin, J. Clin. Invest., 104, 147, 10.1172/JCI6663 Masuda, 2000, Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a livingdonor small bowel recipient, Clin. Pharmacol. Ther., 68, 93, 10.1067/mcp.2000.107912 Ito, 1998, Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver, J. Biol. Chem., 273, 1684, 10.1074/jbc.273.3.1684 Ito, 1997, Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR, Am. J. Physiol., 272, G16 Hirohashi, 2000, Functional and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2), J. Pharmacol. Exp. Ther., 292, 265 Gotoh, 2000, Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/mutidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats, J. Pharmacol. Exp. Ther., 292, 433 Okudaira, 2000, A study of the intestinal absorption of and ester type prodrug, ME3229 in rats: active efflux transport as a cause of poor bioavailability of the active drug, J. Pharmacol. Exp. Ther., 294, 580 Okudaira, 2000, Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine, J. Pharmacol. Exp. Ther., 295, 717 Maliepaard, 2001, Subcellular localization and distribution of the breast cancer resistance protein transporter in nomal human tissues, Cancer Res., 61, 3458 Jonker, 2000, Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan, J. Natl. Cancer. Inst., 92, 1651, 10.1093/jnci/92.20.1651 Sikic, 2000, Enhanced bioavailability of oral paclitaxel by valspodar (PSC833), an inhibitor of small bowel P-glycoprotein and cytochrome P450, Clin. Cancer Res., 6, 4580S Yamazaki, 1996, Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics, Pharm. Res., 13, 497, 10.1023/A:1016077517241 Hsiang, 1999, A novel human hepatic organic anion transporting polypeptide (OATP2), J. Biol. Chem., 274, 37161, 10.1074/jbc.274.52.37161 Nakanishi, 1997, Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080, Cancer. Res., 58, 4118 Nakanishi, 2000, Cancer cell-targeted drug delivery utilizing oligopeptide transport activity, Int. J. Cancer, 88, 274, 10.1002/1097-0215(20001015)88:2<274::AID-IJC20>3.0.CO;2-5 Suzuki, 1997, Role of efflux transport across the blood–brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system, Adv. Drug. Deliv. Rev., 25, 257, 10.1016/S0169-409X(97)00503-6 Kusuhara, 2001, Efflux transport system for drugs at the blood–brain barrier and bloodcerebrospinal fluid barrier (Part 1, 2), Drug. Discov. Today, 6, 150, 10.1016/S1359-6446(00)01632-9 Tamai, 2000, Transporter-mediated permea tion of drugs across the blood–brain barrier, J. Pharm. Sci., 89, 1371, 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D Sadeque, 2000, Increased drug delivery to the brain by P-glycoprotein inhibition, Clin. Pharmacol. Ther., 68, 231, 10.1067/mcp.2000.109156 Ishikawa, 1996, Coordinate induction of MRP/GS-X pump and gammaglutamylcysteine synthetase by heavy metals in human leukemia cells, J. Biol. Chem., 271, 14981, 10.1074/jbc.271.25.14981 Kuo, 1998, Frequent coexpression of MRP/GS-X pump and gammaglutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues, Biochem. Pharmacol., 55, 605, 10.1016/S0006-2952(97)00494-2 Kool, 1999, MRP3 and organic anion transporter able to transport anticancer drugs, Proc. Natl. Acad. Sci. USA, 96, 6914, 10.1073/pnas.96.12.6914 Konig, 1999, Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance, Biochim. Biophys. Acta., 1461, 377, 10.1016/S0005-2736(99)00169-8 Kuwano, 1999, Multidrug resistance-associated protein subfamily transporters and drug resistance, Anticancer Drug. Des., 14, 123 Cole, 1998, Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP, Bioessays, 20, 931, 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J Dantzig, 2001, Reversal of multidrug resistance by the P-glycoprotein modulator, LY335989, from the bench to the clinic, Curr. Med. Chem., 8, 39, 10.2174/0929867013373903 Malingre, 2001, Coadministration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients, Br. J. Cancer, 84, 42, 10.1054/bjoc.2000.1543 Mistry, 2001, In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576, Cancer Res., 61, 749 Ishikawa, 2000, The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design, Clin. Chem. Lab. Med., 38, 893, 10.1515/CCLM.2000.130 Huisman, 2000, Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors, AIDS, 14, 237, 10.1097/00002030-200002180-00005 Lee, 1998, HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter, Biochemistry, 37, 3594, 10.1021/bi972709x Hoetelmans, 1998, Sanctuary site in HIV-1 infection, Antivir. Ther., 3, 13 Turriziani, 2000, May the drug transporter P-glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?, Antimicrob. Agents Chemother., 44, 473, 10.1128/AAC.44.2.473-474.2000 Smit, 1999, Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure, J. Clin. Invest., 104, 1441, 10.1172/JCI7963 Kim, 1998, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J. Clin. Invest., 101, 289, 10.1172/JCI1269 Choo, 2000, Pharmacological inhibition of p-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes, Drug Metab. Dispos., 28, 655 Merry, 1997, Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients, AIDS, 11, F29, 10.1097/00002030-199704000-00001 van Praag, 2000, Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir, AIDS, 14, 1187, 10.1097/00002030-200006160-00016 Schinkel, 1994, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs, Cell, 77, 491, 10.1016/0092-8674(94)90212-7 Jonker, 2001, Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene, Mol. Cell. Biol., 21, 5471, 10.1128/MCB.21.16.5471-5477.2001 Wijnholds, 1997, Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein, Nat. Med., 3, 1275, 10.1038/nm1197-1275 Wijnholds, 2000, Multidrug resistance protein 1 protects the chroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier, J. Clin. Invest., 105, 279, 10.1172/JCI8267 Sekine, 2000, The multispecific organic anion transporter (OAT) family, Pflugers Arch., 440, 337, 10.1007/s004240000297 Hosoyamada, 1999, Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney, Am. J. Physiol., 276, F122 Cihlar, 1999, The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1, Mol. Pharmacol., 56, 570, 10.1124/mol.56.3.570 Jung, 2001, Characterization of ochratoxin A transport by human organic anion transporters, Life Sci., 69, 2123, 10.1016/S0024-3205(01)01296-6 Wada, 2000, Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs, J. Pharmacol. Exp. Ther., 294, 844 Jariyawat, 1999, The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1, J. Pharmacol. Exp. Ther., 290, 672 Cihlar, 2001, Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs, Nucleosides Nucleotides Nucleic Acids, 20, 641, 10.1081/NCN-100002341 Cihlar, 2000, Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1, Anal. Biochem., 283, 49, 10.1006/abio.2000.4633 Mulato, 2000, Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1, J. Pharmacol. Exp. Ther., 295, 10 Apiwattanakul, 1999, Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes, Mol. Pharmacol., 55, 847 Rowinsky, 1994, Phase I and Pharmacological study of novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) ad ministered as a ninety-minute infusion every 3 weeks, Cancer Res., 54, 427 Araki, 1993, Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11, Jpn. J. Cancer Res., 84, 697, 10.1111/j.1349-7006.1993.tb02031.x Kanedam, 1990, Nonlinear pharmacokinetics of CPT-11 in rats, Cancer Res., 50, 1721 Chu, 1997, Multispecific organic anion transporter (cMOAT) is responsible for the bilialy excretion of the camptothecin derivative irinotecan, CPT-11, and its metabolites in rats, J. Pharmacol. Exp. Ther., 281, 304 Chu, 1997, Multiplicity of biliary excretion mechanisms for the camptothecin dericative irinotecan, CPT-11, and its metabolites in rats, Cancer Res., 57, 1934 Chu, 1998, Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters, Cancer Res., 58, 5137 Keppler, 2000, Hepatic secretion of conjugated drugs and endogenous substance, Semin. Liver Dis., 20, 265, 10.1055/s-2000-9391 Kullak-Ublick, 2000, Hepatic transport of bile salts, Semin. Liver Dis., 20, 273, 10.1055/s-2000-9426 Inui, 2000, Cellular and molecular aspects of drug transport in the kidney, Kidney Int., 58, 944, 10.1046/j.1523-1755.2000.00251.x Oguchi, 1993, Pharmacokinetics of temocapril and enalapril in patients with various degree of renal insufficiency, Clin. Pharmacokinet., 24, 421, 10.2165/00003088-199324050-00006 Ishizuka, 1997, Temocaprilat, a novel angiotensin converting enzyme inhibitor, is excreted into bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyper-biliruminemic mutant rats (EHBR), J. Pharmacol. Exp. Ther., 280, 1304 Ishizuka, 1999, Species differences in the transport activity for organic anions across the bile canalicular membrane, J. Pharmacol. Exp. Ther., 290, 1324 Konig, 2000, A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane, Am. J. Physiol. Gastrointest. Liver Physiol., 278, G156, 10.1152/ajpgi.2000.278.1.G156 Abe, 1999, Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1, J. Biol. Chem., 274, 17159, 10.1074/jbc.274.24.17159 Kakyo, 1999, Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1, Gastroenterology, 117, 770, 10.1016/S0016-5085(99)70333-1 Zhang, 1997, Cloning and functional expression of a human liver organic cation transporter, Mol. Pharmacol., 51, 913, 10.1124/mol.51.6.913 Kovaril, 1999, Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin, Clin. Pahrmacol. Ther., 66, 391, 10.1053/cp.1999.v66.a101462 Hedman, 1991, Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans, Clin. Pharmacol. Ther., 49, 256, 10.1038/clpt.1991.26 Hedman, 1990, Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine, Clin. Pharmacol. Ther., 47, 20, 10.1038/clpt.1990.3 Muck, 1999, Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients, Clin. Pharmacol. Ther., 65, 251, 10.1016/S0009-9236(99)70104-9 Sasaki, M., Suzuki, H., Ito, K., Abe, T. and Sugiyama, Y.: Transcellular transport of organic anions across double-transfected MDCK II cell monolayer expressing both human organic anion transporting polypeptide (OATP2/SLC21A6) and multidrug resistance associated protein 2 (MRP2/ABCC2). J. Biol. Chem., in press. Alexandridis, 2000, Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil, Am. J. Med., 109, 261, 10.1016/S0002-9343(00)00514-3 SoRelle, 2001, Baycol withdrawn from market, Circulation, 104, E9015 Schwarz, 2000, P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans, Int. J. Clin. Pharmacol. Ther., 38, 161, 10.5414/CPP38161 Suzuki, 2000, Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine, Eur. J. Pharm. Sci., 12, 3, 10.1016/S0928-0987(00)00178-0 Wacher, 2001, Active secretion and enterocytic drug metabolism barriers to drug absorption, Adv. Drug Deliv. Rev., 46, 89, 10.1016/S0169-409X(00)00126-5 Cvetkovic, 1999, OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine, Drug Metab. Dispos., 27, 866 Bailey, 2001, Reduction of fexofenadine bioavailability by fruit juices [abstract], Clin. Pharmacol. Ther., 69, 21 Johne, 1999, Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort, Clin. Pharmacol. Ther., 66, 338, 10.1053/cp.1999.v66.a101944 Durr, 2000, St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4, Clin. Pharmacol. Ther., 68, 598, 10.1067/mcp.2000.112240 Fromm, 2000, The effect of rifampin treatment on intestinal expression of human MRP transporters, Am. J. Pathol., 157, 1575, 10.1016/S0002-9440(10)64794-3 Synold, 2001, The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux, Nature Med., 7, 584, 10.1038/87912 Geick, 2001, Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin, J. Biol. Chem., 276, 14581, 10.1074/jbc.M010173200 Masuyama, 2001, The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse, Mol. Cell Endocrinol., 172, 47, 10.1016/S0303-7207(00)00395-6 Ueda, 2001, Inhibition of the bilialy excretion of methotrexate by probenecid in rats: Quantitative prediction of the interaction from in vitro data, J. Pharmacol. Exp. Ther., 297, 1036 Mayatepek, 2000, Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency, Hum. Mutat., 15, 118, 10.1002/(SICI)1098-1004(200001)15:1<118::AID-HUMU28>3.0.CO;2-8 Ito, 2001, Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects, Pharmacogenetics, 11, 175, 10.1097/00008571-200103000-00008 Kerb, 2001, ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2, Pharmacogenetics, 2, 51, 10.1517/14622416.2.1.51 Nezu, 1999, Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter, Nat. Genet., 21, 91, 10.1038/5030 Hoffmeyer, 2000, Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc. Natl. Acad. Sci. USA, 97, 3473, 10.1073/pnas.97.7.3473 Cascorbi, 2001, Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transpsorter MDR1 gene in white subjects, Clin. Pharmacol. Ther., 69, 169, 10.1067/mcp.2001.114164 Ameyaw, 2001, MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity, Pharmacogenetics, 11, 217, 10.1097/00008571-200104000-00005 Kim, 2001, Identification of functionally variant MDR1 alleles among European Americans and African Americans, Clin. Pharmacol. Ther., 70, 189, 10.1067/mcp.2001.117412 Tirona, 2001, Polymorphisms in oatp-c. Identification of multiple allelic variants associated with altered transport activity among European- and African-americans, J. Biol. Chem., 276, 35669, 10.1074/jbc.M103792200 Adachi, 2001, Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein, Pharm. Res., 18, 1660, 10.1023/A:1013358126640 Yamazaki, 2001, In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results, J. Pharmacol. Exp. Ther., 296, 723 Pauli Magnus, 2001, Pglycoprotein-mediated transport of digitoxin, alphamethyldigoxin and beta-acetyldigoxin, Naunyn. Schmiedebergs. Arch. Pharmacol., 363, 337, 10.1007/s002100000354 Cui, 2001, Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2, Mol. Pharmacol., 60, 934, 10.1124/mol.60.5.934 Doppenschmitt, 1998, Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter, J. Pharm. Res., 15, 1001, 10.1023/A:1011965707998 Wang, 2000, In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein, Drug Metab. Dispos., 28, 316 Eneroth, 2001, Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction, Eur. J. Pharm. Sci., 12, 205, 10.1016/S0928-0987(00)00117-2 Fernandes, 1998, Technological advances in high-throughput screening, Curr. Opin. Chem. Biol., 2, 597, 10.1016/S1367-5931(98)80089-6 Polli, 2001, Rational use of in vitro P-glycoprotein assays in drug discovery, J. Pharmacol. Exp. Ther., 299, 620 Seelig, 2000, Structure-activity relationship of P-glycoprotein substrates and modifiers, Eur. J. Pharm. Sci., 12, 31, 10.1016/S0928-0987(00)00177-9 Ekins, 2000, Progress in predicting human ADME parameters in silico, J. Pharmacol. Toxicol. Methods, 44, 251, 10.1016/S1056-8719(00)00109-X Sugiyama, Y., Kato, Y. and Ito, K.: Quantitative prediction: metabolism, transport in the liver. in “Preclinical and clinical evaluation of drug-drug interactions” Vol II in Advances in drug development. ISE Press, Inc. in press. Sugiyama, 2001, Characterization of the efflux transport of 17β-estradiol-D-17β-glucuronide from the brain across the blood–brain barrier, J. Pharmacol. Exp. Ther., 298, 316 Hasegawa, 2002, Functional involvement of rat organic anion transporter 3 (rOAT3) in the renal uptake of organic anions, J. Pharmacol. Exp. Ther., 300, 746, 10.1124/jpet.300.3.746 Nagata, 2002, Expression and functional characterization of rat organic anion transporter 3 (Slc22a8) in the choroids plexus, Mol. Pharmacol., 61, 982, 10.1124/mol.61.5.982 Boyd, 2000, Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion, J. Clin. Pharmacol., 40, 91, 10.1177/00912700022008612 Malingre, 2001, Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel, J. Clin. Oncol., 19, 1160, 10.1200/JCO.2001.19.4.1160 Meerum Terwogt, 1999, Coadministration of oral cyclosporin A enables oral therapy with paclitaxel, Clin. Cancer. Res., 5, 3379 Siedlik, 1999, Erythromycin coadministration increases plasma atorvastatin concentrations, J. Clin. Pharmacol., 39, 501, 10.1177/009127009903900510 Freeman, 1987, Cyclosporin-erythromycin interaction in normal subjects, Br. J. Clin. Pharmacol., 23, 776 Gupta, 1988, Erythromycin enhances the absorption of cyclosporin, Br. J. Clin. Pharmacol., 25, 401, 10.1111/j.1365-2125.1988.tb03320.x Gupta, 1989, Cyclosporin-erythromycin interaction in renal transplant patients, Br. J. Clin. Pharmacol., 27, 475, 10.1111/j.1365-2125.1989.tb05396.x Davit, 1999, FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling, J. Clin. Pharmacol., 39, 899, 10.1177/00912709922008515 Grub, 2001, The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients, Eur. J. Clin. Pharmacol., 57, 115, 10.1007/s002280100277 Floren, 1997, Tacrolimus oral bioavailability doubles with coadministration of ketoconazole, Clin. Pharmacol. Ther., 62, 41, 10.1016/S0009-9236(97)90150-8 Westphal, 2000, Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein, Clin. Pharmacol. Ther., 68, 6, 10.1067/mcp.2000.107579 Gramatte, 1999, Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil, Clin. Pharmacol. Ther., 66, 239, 10.1016/S0009-9236(99)70031-7 Hamman, 2001, The effect of rifampin administration on the disposition of fexofenadine, Clin. Pharmacol. Ther., 69, 114, 10.1067/mcp.2001.113697 Hebert, 1999, Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers, J. Clin. Pharmacol., 39, 91, 10.1177/00912709922007499 Westphal, 2000, Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug-drug interaction, Clin. Pharmacol. Ther., 68, 345, 10.1067/mcp.2000.109797